The Cooper Companies stock: Why it's a top growth pick for long-term investors

Looking for steady growth in healthcare? The Cooper Companies stands out with strong earnings momentum and a Zacks top rank. This could matter for your portfolio whether you're investing from the U.S., Europe, or globally. ISIN: US2166481027

You're scanning the market for reliable growth stories, and The Cooper Companies (COO) deserves your attention. This Nasdaq-listed medical device leader focuses on vision care and women's health, two resilient sectors that keep delivering even when broader markets wobble. With a Zacks Rank signaling strong potential and upward earnings revisions, it's positioned as a top growth stock right now.

As of: 08.04.2026

By Elena Voss, Senior Equity Analyst: The Cooper Companies drives innovation in contact lenses and surgical devices, making it a key player in essential healthcare markets.

What The Cooper Companies Does and Why It Matters

The Cooper Companies operates through two main pillars: CooperVision and CooperSurgical. CooperVision leads in contact lenses, serving millions with products for daily wear, multifocal needs, and specialty lenses for conditions like astigmatism. You benefit from this because vision correction is a daily essential, not a luxury, driving consistent demand across demographics.

CooperSurgical, meanwhile, provides devices and fertility solutions for women's health, including embryo transfer catheters and surgical tools used in OB/GYN practices. This segment taps into growing needs in reproductive health and minimally invasive procedures. For you as an investor, these areas offer defensive qualities—people prioritize eye care and family planning regardless of economic cycles.

The company's global footprint spans over 100 countries, with a heavy emphasis on North America and Europe. This diversification shields you from regional slowdowns. Revenue for the year ending October 31, 2024, reached $3.895 billion, up from $3.593 billion the prior year, showing solid expansion.

Financial Strength and Growth Momentum

Profit before tax jumped to $582.3 million in fiscal 2024 from $412.9 million, reflecting operational leverage. Adjusted EPS soared to 197 cents from 37.25 cents, a remarkable 429% growth that underscores efficiency gains. You see this as a sign of management's ability to scale profitably.

Analysts project fiscal 2026 EPS at $4.62, with six upward revisions in the last 60 days adding $0.12 to the consensus. The average earnings surprise of +4.1% means COO often beats expectations, a trait you want in your growth holdings. With a PEG ratio of 0.10, the stock looks undervalued relative to its growth prospects.

This momentum positions COO favorably in the medical devices space. While the P/E stands at 53.1, the low PEG suggests you're not overpaying for that growth. For long-term investors like you, these metrics signal a stock that can compound wealth steadily.

Competitive Edge in Vision and Surgical Markets

CooperVision holds a strong position in the $10 billion contact lens market, innovating with silicone hydrogel lenses that offer superior comfort and oxygen flow. Products like Biofinity and MyDay address key consumer pain points, helping you capture share from traditional glasses and daily disposables. This innovation drives repeat purchases, stabilizing your revenue stream.

In women's health, CooperSurgical's Parata and Gynemesh portfolios support fertility clinics and surgeons worldwide. As IVF demand rises with delayed childbearing trends, this segment grows at double-digit rates. You gain exposure to a market less sensitive to recessions, as healthcare needs persist.

Compared to peers like Johnson & Johnson Vision or Bausch + Lomb, Cooper's focus on niches gives it pricing power and loyalty. No dividends yet, but reinvestment fuels R&D, which hit meaningful levels in recent years. This strategy suits you if you're building for the next decade.

Analyst Views: What Banks and Research Houses Say

Reputable analysts view The Cooper Companies positively, with Zacks highlighting it as a top growth stock due to its Zacks Rank, Growth Score, and VGM Style Score. Six analysts lifted fiscal 2026 earnings estimates in the last 60 days, pushing the consensus to $4.62 per share. This upward momentum reflects confidence in sustained performance.

The stock's average earnings beat of +4.1% bolsters this outlook, placing COO on short lists for investors seeking reliable outperformers. While specific price targets from individual banks aren't detailed in recent public summaries, the consensus leans bullish on growth potential. You can weigh this against your risk tolerance when deciding allocation.

These views come from established research like Zacks, which tracks revisions and surprises rigorously. For you, this means institutional backing without hype—purely data-driven endorsement of COO's trajectory.

Why This Stock Matters to You as an Investor

Whether you're in the U.S., Europe, or elsewhere, The Cooper Companies offers global relevance. Traded on Nasdaq in USD (ISIN: US2166481027), it's accessible via most brokers. Its healthcare focus provides a hedge against tech volatility, appealing if you're diversifying beyond megacaps.

Recent 52-week range from $61.78 to $89.83 shows resilience, with a 50-day moving average supporting upward trends. You might buy now if growth metrics align with your goals, but always size positions based on your research. The lack of dividend means it's for those comfortable with capital appreciation plays.

For younger investors building wealth, COO's story fits: essential products, global reach, and analyst tailwinds. It answers 'should you buy now?' with a qualified yes for growth-oriented portfolios, backed by fundamentals.

Risks and What to Watch Next

Regulatory hurdles in medtech can delay product launches, so watch FDA approvals closely. Supply chain issues for specialty materials might pressure margins, though diversification helps. Competition intensifies if big pharma enters vision care more aggressively.

Macro risks include healthcare spending cuts in recessions, but essentials like contacts buffer this. Currency fluctuations affect international sales, relevant for your global view. Track quarterly earnings for EPS beats and guidance—key for near-term moves.

What should you watch next? Upcoming fiscal 2026 estimates revisions and segment growth. If upward trends hold, COO could reward patience. Balance this with your portfolio needs.

Final Thoughts for Your Portfolio

Integrating The Cooper Companies means betting on proven growth in vital health sectors. Its financial trajectory, competitive moats, and analyst support make a compelling case. You decide based on your horizon—long-term holders may find it attractive now.

Stay informed via official channels and monitor catalysts like earnings. This evergreen profile equips you to act confidently. Diversify, research deeply, and align with your goals.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.